These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1269 related items for PubMed ID: 15667949

  • 1. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):318-28. PubMed ID: 15667949
    [Abstract] [Full Text] [Related]

  • 2. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.
    Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):706-13. PubMed ID: 15936549
    [Abstract] [Full Text] [Related]

  • 3. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):735-42. PubMed ID: 14967428
    [Abstract] [Full Text] [Related]

  • 4. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV.
    Int J Radiat Oncol Biol Phys; 2006 Sep 01; 66(1):126-34. PubMed ID: 16904518
    [Abstract] [Full Text] [Related]

  • 5. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF, Scott CB, Dundas GS, Mohiuddin M, Meredith RF, Rubin P, Weigensberg IJ.
    Am J Clin Oncol; 2007 Aug 01; 30(4):368-76. PubMed ID: 17762437
    [Abstract] [Full Text] [Related]

  • 6. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S, Flickinger JC, Kalend AM, Deutsch M, Belani CP, Sciurba FC, Luketich JD, Greenberger JS.
    Radiat Oncol Investig; 1999 Aug 01; 7(5):297-308. PubMed ID: 10580899
    [Abstract] [Full Text] [Related]

  • 7. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, Kris MG, Ling CC, Leibel SA.
    Cancer; 2005 May 15; 103(10):2118-27. PubMed ID: 15830346
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):374-87. PubMed ID: 15380569
    [Abstract] [Full Text] [Related]

  • 9. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
    Kim TH, Cho KH, Pyo HR, Lee JS, Han JY, Zo JI, Lee JM, Hong EK, Choi IJ, Park SY, Shin KH, Kim DY, Kim JY.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):995-1002. PubMed ID: 15990000
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS, Yoon SM, Choi EK, Yi BY, Kim JH, Ahn SD, Lee SW, Shin SS, Lee JS, Suh C, Kim SW, Kim DS, Kim WS, Park HJ, Park CI.
    Int J Radiat Oncol Biol Phys; 2005 May 01; 62(1):76-81. PubMed ID: 15850905
    [Abstract] [Full Text] [Related]

  • 11. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J, Carolina Conformal Therapy Consortium.
    J Clin Oncol; 2004 Nov 01; 22(21):4329-40. PubMed ID: 15514374
    [Abstract] [Full Text] [Related]

  • 12. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A, Girard N, Chapet O, Khodri M, Kubas A, Souquet PJ, Mornex F.
    Cancer Radiother; 2009 Jul 01; 13(4):298-304. PubMed ID: 19525134
    [Abstract] [Full Text] [Related]

  • 13. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1369-77. PubMed ID: 15050312
    [Abstract] [Full Text] [Related]

  • 14. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
    Rojas AM, Lyn BE, Wilson EM, Williams FJ, Shah N, Dickson J, Saunders MI.
    Cancer; 2006 Sep 15; 107(6):1321-30. PubMed ID: 16902985
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K, Nemoto K, Saito H, Ogawa Y, Takai Y, Yamada S.
    Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):626-9. PubMed ID: 15936536
    [Abstract] [Full Text] [Related]

  • 16. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J.
    Radiother Oncol; 2005 May 01; 75(2):157-64. PubMed ID: 15890421
    [Abstract] [Full Text] [Related]

  • 17. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH, Ahn SJ, Pyo HR, Kim KS, Kim YC, Moon SH, Han JY, Kim HT, Koom WS, Lee JS.
    Int J Radiat Oncol Biol Phys; 2009 Aug 01; 74(5):1397-404. PubMed ID: 19117690
    [Abstract] [Full Text] [Related]

  • 18. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.
    Clin Cancer Res; 2005 May 01; 11(9):3342-8. PubMed ID: 15867233
    [Abstract] [Full Text] [Related]

  • 19. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1019-34. PubMed ID: 15752881
    [Abstract] [Full Text] [Related]

  • 20. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE, Mychalczak B, Fuks Z, Hanley J, Burman C, Ling CC, Armstrong J, Ginsberg R, Kris MG, Raben A, Leibel S.
    Cancer J; 2000 Mar 15; 6(2):82-7. PubMed ID: 11069224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.